For informational and research purposes only.
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Metabolism, recovery and emerging research
Human trials and laboratory findings explain interest in thymosin alpha-1, but cancer type, companion medicines and clinical outcomes determine relevance.
Read articleMicrodosing covers different semaglutide regimens. Separate approved titration, new observational reports and registered trials from claims they have not established.
Read articleSingle-agent trials show cagrilintide has activity of its own, while separating weight loss, glucose effects and specific safety findings.
Read articleSTEP 9 found better pain and physical-function outcomes in adults with obesity and knee osteoarthritis. Learn why that is different from cartilage repair.
Read articleThe US mazdutide trial broadens the evidence, but actual enrollment, eligibility and small treatment groups define how far its results can travel.
Read articleHigher-dose trials show substantial weight reduction, alongside important differences in exposure, analysis methods and gastrointestinal tolerability.
Read articlePetrelintide builds on a familiar fullness hormone with a longer-acting molecule and new formulation possibilities.
Read articleARISE-3 and the small corneal-defect trial answer different eye-health questions. Their findings do not establish an injected recovery combination.
Read articlePersistent digestive symptoms need an explanation. Understand the role of history, targeted tests, symptom tracking and the limits of KPV research.
Read articleWhy gonadorelin's fertility role depends on the location of the hormone problem, with evidence from male hypogonadism and hypothalamic amenorrhea.
Read articleUnderstand the separate desire, distress, and satisfying-event results in RECONNECT, including score changes, response thresholds and dropout.
Read articleA closer look at ipamorelin's bowel-surgery trial, its nonsignificant meal-tolerance result, serious-event uncertainty and limits for fitness claims.
Read article73–84 of 323 articles
